Skip to main content
SpringerLink
Log in

Is NAB-P + GEM cost effective in the UK?

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2013 values

Reference

  • Gharaibeh M, et al. Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer. British Journal of Cancer : 19 Mar 2015. Available from: URL: http://dx.doi.org/10.1038/bjc.2015.65

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Is NAB-P + GEM cost effective in the UK?. PharmacoEcon Outcomes News 725, 18 (2015). https://doi.org/10.1007/s40274-015-2032-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-015-2032-y

Search

Navigation